A combination regimen may be effective in patients with relapsed or refractory multiple myeloma and moderate to severe renal impairment, especially in those with advanced disease requiring hemodialysis.


In a recent study, researchers compared the safety and efficacy of a certain therapy with conventional treatment for patients with relapsed or refractory multiple myeloma.

Read More

By Megan Brooks

NEW YORK (Reuters Health) - For patients with bone metastases due to breast cancer, prostate cancer, or multiple myeloma, dosing zoledronic acid every 12 weeks works as well as the standard dosing interval of every four weeks, according to a randomized controlled trial.

Read More

Subscribe to Hematologic Malignancies